ClinicalTrials.gg
RecruitingNCT05884502Updated Jun 1, 2023

A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke

A Phase 4 interventional study of combination of high-dose rosuvastatin and ezetimibe and high-dose rosuvastatin single administration in Dyslipidemias and Stroke, Acute Ischemic, sponsored by Korea University Anam Hospital. Recruiting at 3 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-06-01.

Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Sep 2022, registered Apr 2023).
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing rosuvastatin in Dyslipidemias — 2 open to participants now, 2 under way, none of them phase 3. rosuvastatin · Dyslipidemias.

Planned enrollment
10th of 42
330 · median 128
Started
2022
with 3 others
Phase 4
13 of 42
1 open now
Registered
38th of 42
by date
Lead sponsor
2 of 42
Korea University Anam Hospital

Among the 42 studies testing rosuvastatin in Dyslipidemias, this one is the 10th largest by planned enrollment, is one of 4 that started in 2022, is one of 13 in phase 4, and was the 38th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

2 of the 42 studies testing rosuvastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing rosuvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

High-intensity statins are recommended for secondary prevention of stroke in patients with atherosclerotic ischemic stroke. According to the guidelines of the American Heart Association and the American Stroke Society, high-intensity or high-dose statins are recommended for high-risk groups of atherosclerotic cardiovascular disease (ASCVD). Statin therapy is recommended even if it is less than 100 mg/dL. The 2016 ESC/EAS and 2017 AACE guidelines include ischemic stroke and transient cerebral ischemic attacks caused by atherosclerosis in ASCVD, classifying them as ultra-high-risk groups, and recommending LDL cholesterol of less than 70 mg/dL as a treatment goal. The recently published guidelines for dyslipidemia in Korea also recommend that the target level of LDL cholesterol in patients with atherosclerotic ischemic stroke and transient ischemic attack be reduced to less than 70 mg/dL or 50% or more from the baseline.

According to a previous study on the efficacy and safety of high-intensity rosuvastatin in patients with ischemic stroke, it is not clear whether the use of rosuvastatin 20 mg prevents recurrence of cerebral infarction in the acute stage, but it is safe and effective for hemorrhagic conversion of cerebral infarction. In addition, the results were shown when rosuvastatin and ezetimibe were combined in patients with high cardiovascular risk, LDL cholesterol and total cholesterol decreased more in the combined group than in the single agent group. In a study comparing the group whose LDL cholesterol target was reduced to 70 mg/dL or less after stroke and the group maintained at 90-110 mg/dL, the group whose LDL cholesterol was controlled to 70 mg/dL or less It was confirmed that the incidence of cardiovascular disease was reduced. Existing studies aimed at general high-risk groups, not specific disease groups, and as in this study, studies were not conducted on a single disease group called acute stroke. In addition, there are only limited studies on the effectiveness and safety of diseases that occur mainly in the elderly, such as acute stroke. Therefore, there are currently no studies on the clinical efficacy and safety of high-intensity rosuvastatin and ezetimibe combination therapy for patients with acute cerebral infarction.

Read the detailed description

Multicenter, randomized controlled trial to compare the efficacy and safety of the test group (high-dose rosuvastatin and ezetimibe combined administration group) and control group (high-dose rosuvastatin single administration group) to achieve the target LDL-C level in patients who have recently experienced an ischemic stroke; It is an open-label, investigator-led clinical trial.

In this clinical trial, treatment is performed according to the general treatment procedure for patients who have recently had an ischemic stroke. Subjects who agree to participate in the clinical trial and satisfy the selection and exclusion criteria are the test group (combination of high-dose rosuvastatin and ezetimibe). Administration group) and control group (high-dose rosuvastatin single administration group) are randomly assigned in a 1:1 ratio.

Clinical investigational drugs according to randomization are administered to hospitalized patients, and when discharged, they are allowed to take the provided clinical investigational drugs for a total of 90 days. After the baseline, on the 7th day or at discharge (1st follow-up), and on the 30th day (2nd follow-up), compliance with medication and occurrence of adverse reactions are observed, and on the 90th day (3rd follow-up), lipid concentration test is performed. Check LDL-C levels and compare with baseline LDL-C levels.

03

Conditions studied

  • Dyslipidemias
  • Stroke, Acute Ischemic
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Those with primary hypercholesterolemia among those whose lesions were confirmed by brain CT or MRI within 48 hours of the onset of ischemic stroke
  2. Adults 19 years of age or older
  3. Patients who agreed to participate in this study

Exclusion criteria

Exclusion Criteria:

  1. Patients scheduled for carotid endarterectomy or stenting, cerebral artery stenting, coronary angioplasty and stenting, or coronary artery bypass surgery within 3 months
  2. Patients with malignant tumors that have not been cured
  3. Patients who have participated in other drug clinical trials within the last 30 days
  4. Patients expected to experience side effects when taking rosuvastatin and ezetimibe
  5. Patients who did not consent to participate in this study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Combination therapy

    combination of high-dose rosuvastatin and ezetimibe

    Drug: combination of high-dose rosuvastatin and ezetimibe

  • Active comparator
    Single therapy

    high-dose rosuvastatin single administration group

    Drug: high-dose rosuvastatin single administration

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute value of LDL-C (low-density lipoprotein cholesterol) reduction

    low-density lipoprotein cholesterol reduction at 90 days after enrollment

    Time frame: 90 days after enrollment

Other outcomes

  1. Percentage of reaching target LDL-C (low-density lipoprotein cholesterol) levels

    LDL-C (low-density lipoprotein cholesterol) \< 70 mg/dL or 50% or more decrease from baseline

    Time frame: 90 days after enrollment

  2. Changes in total cholesterol, HDL-C (high-density lipoprotein cholesterol), and TG (Triglyceride) levels at 3 months compared to randomization

    Changes in total cholesterol, HDL-C (high-density lipoprotein cholesterol), and TG (Triglyceride) levels at 90 days

    Time frame: 90 days after enrollment

  3. Clinical event occurence- major cardiovascular adverse event (MACE)

    MACE; relapse of stroke, cardiovascular death, other death, occurrence of coronary artery disease, occurrence of myocardial infarction requiring percutaneous coronary intervention

    Time frame: 90 days after enrollment

  4. Clinical Stroke Scale

    NIHSS (National Institute of Health stroke scale) score,

    Time frame: 90 days after enrollment

  5. Clinical Stroke Scale

    mRS (modified Rankins scale) score

    Time frame: 90 days after enrollment

  6. Safety endpoints

    newly diagnosed diabetes mellitus

    Time frame: 90 days after enrollment

  7. Safety endpoints

    newly developed muscle symptoms measured with statin related muscle symptoms questionnaire (SAMS-Q)

    Time frame: 90 days after enrollment

  8. Safety endpoints

    liver enzyme levels (AST in IU/L, ALT in IU/L)

    Time frame: 90 days after enrollment

  9. Safety endpoints

    development of intracranial hemorrhage

    Time frame: 90 days after enrollment

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2023, 15 months after the start.

Of 37 phase 4 interventional studies under Dyslipidemias, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 40. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
Jun 1, 2023
StartActual
Sep 1, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2024
Last update
Jun 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05884502
Responsible party
Yu, Sungwook (Professor, Korea University Anam Hospital) — Principal investigator
First posted
Jun 1, 2023
Start date
Sep 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jun 1, 2023

Study contacts

Sungwook Yu, M.D.
Contact
song4yu@korea.ac.kr
82-2-920-5510

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe

Start the discussion